Review anchor
Alpha-1D adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Alpha-1D adrenergic receptor
CHEMBL223
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-1D adrenergic receptor as ChEMBL target CHEMBL223, mapped to UniProt P25100. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL223
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P25100
Alpha-1D adrenergic receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Alpha-1D adrenergic receptor matters
Alpha-1D adrenergic receptor is reviewed as Alpha-1D adrenergic receptor (UniProt P25100); Alpha-1D adrenergic receptor shows late clinical disease relevance led by hyperplasia.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 147 approved drugs, 2885 compounds, and 328 assays, with lead potency reaching pChEMBL 10.8.
Protein context
Alpha-1D adrenergic receptor
Alpha-1D adrenergic receptor Sequence length is 572 aa.
Review this target as Alpha-1D adrenergic receptor, mapped to UniProt P25100. Sequence length is 572 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P25100
Protein
Disease context
hyperplasia
Alpha-1D adrenergic receptor shows late clinical disease relevance led by hyperplasia. 1 linked drug keep the rationale reviewable. Linked drugs include NAFTOPIDIL.
Start review with hyperplasia because it currently carries late clinical support. Linked drugs include NAFTOPIDIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Late clinical
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 147 approved drugs, 2885 compounds, and 328 assays for this target. The dominant activity type is KI. CHEMBL778 is the current potency anchor at pChEMBL 10.8.
Use CHEMBL778 as the tractability anchor when discussing potency (pChEMBL 10.8).
Activity source · ChEMBL 36 via Core Engine
147 approved
pChEMBL 10.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Alpha-1D adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P25100, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why hyperplasia is currently treated as late clinical support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2885
Total Compounds
328
Total Assays
147
Approved Drugs
IC50: 1027.0, KI: 2313.0, EC50: 247.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL778
|
10.8 | Ki | Approved |
|
|
No preferred name
CHEMBL200446
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL4128084
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL324090
|
10.4 | Ki | Clinical |
|
|
No preferred name
CHEMBL196817
|
10.3 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
|
2015 |
|
|
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
|
2011 |
|
|
INDACATEROL
CHEMBL1095777
|
2009 |
|
|
SILODOSIN
CHEMBL24778
|
2008 |
|
|
ALFUZOSIN
CHEMBL709
|
2003 |
|
|
APOMORPHINE
CHEMBL53
|
2001 |
|
|
NAFTOPIDIL
CHEMBL142635
|
1999 |
|
|
DEXMEDETOMIDINE
CHEMBL778
|
1999 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
RALOXIFENE
CHEMBL81
|
1997 |
|
|
BRIMONIDINE
CHEMBL844
|
1996 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
AZELASTINE HYDROCHLORIDE
CHEMBL1200809
|
1996 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
SALMETEROL
CHEMBL1263
|
1994 |
|
|
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
|
1994 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CISAPRIDE
CHEMBL1729
|
1993 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
DAPIPRAZOLE
CHEMBL1201216
|
1990 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
ASTEMIZOLE
CHEMBL296419
|
1988 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
|
|
BUSPIRONE
CHEMBL49
|
1986 |
|
|
LABETALOL
CHEMBL429
|
1984 |
|
|
CYCLIZINE
CHEMBL648
|
1982 |
|
|
GUANABENZ
CHEMBL420
|
1982 |
|
|
GENTIAN VIOLET
CHEMBL64894
|
1982 |
|
|
TRAZODONE
CHEMBL621
|
1981 |
|
|
AMOXAPINE
CHEMBL1113
|
1980 |
|
|
MAPROTILINE
CHEMBL21731
|
1980 |
|
|
DOBUTAMINE
CHEMBL926
|
1978 |
|
|
BROMOCRIPTINE
CHEMBL493
|
1978 |
|
|
CLEMASTINE
CHEMBL1626
|
1977 |
|
|
PRAZOSIN
CHEMBL2
|
1976 |
|
|
CLONIDINE
CHEMBL134
|
1974 |
|
|
DROPERIDOL
CHEMBL1108
|
1970 |
|
|
DOXEPIN
CHEMBL1628227
|
1969 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
EPINEPHRINE
CHEMBL679
|
1965 |
|
|
NORTRIPTYLINE
CHEMBL445
|
1964 |
|
|
THIORIDAZINE
CHEMBL479
|
1962 |
|
|
CYPROHEPTADINE
CHEMBL516
|
1961 |
|
|
AMITRIPTYLINE
CHEMBL629
|
1961 |
|
|
ATROPINE
CHEMBL517712
|
1960 |
Source Header